✦ LIBER ✦

1203 ORAL Long-term Survival in a Phase II Study of Belagenpumatucel-L (TGF-β Antisense Modified Tumour Cell Vaccine) in Non-small Cell Lung Cancer (NSCLC)

✍ Scribed by E. Juhasz; E. Carrier; D.F. Shawler

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of Belagenpumatucel-L, a

✍ Nemunaitis, J; Nemunaitis, M; Senzer, N; Snitz, P; Bedell, C; Kumar, P; Pappen, 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 149 KB

Pre-operative chemoradiotherapy in non-s

✍ A. Favaretto; A. Paccagnella; L. Tomio; F. Sartori; A. Cipriani; R. Zuin; L. Ref 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 681 KB

Final results of a phase II study of Gem

✍ C. Sacco; G. Cartei; A. Sibau; A. Bearz; M. Gusella; A. Iop; E. Vigevani; V.M. D 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 183 KB

P-621 Concurrent hyperfractionated radio

✍ Jeremic, B.; Milicic, B.; Radosavljevic-Asic, G. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 124 KB

10-year long-term survival (LTS) of indu

✍ Eberhardt, Wilfried Ernst Erich; Gauler, Thomas Christoph; LePechoux, Cecile; St 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 824 KB